Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.61 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.61 |
| ▸ | BLM | P54132 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274518 | 1.00 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL198313 | 1.00 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL7268076 | 0.98 | LMNA (0.61) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL3916189 | 0.98 | LMNA (0.64) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL2062723 | 0.98 | LMNA (0.64) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL415802 | 0.98 | LMNA (0.64) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL8987487 | 0.97 | LMNA (0.59) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Iodide SCHEMBL16713395 | 0.97 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| Hydrochloric Acid SCHEMBL7269400 | 0.97 | LMNA (0.62) | LMNACYP2D6CYP2C9HSD17B10CHRM2 | |
| SCHEMBL19105458 | 0.85 | CYP2D6 (0.51) | LMNACYP2D6CYP2C9HSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | claimed |
| CN-114805100-A | Preparation method of oxybutynin hydrochloride | 南京亿华药业有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-10449173-B2 | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions | ALLERGAN SALES, LLC (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3287122-B1 | DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS FOR TREATING OVERACTIVE BLADDERS. | ALLERGAN SALES LLC (US) | 2019-04-17 | — | — | EP | disclosed |
| CN-109553705-A | A kind of catalytic component and preparation method thereof for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109553712-A | A kind of catalytic component and its catalyst for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109553704-A | A kind of catalytic component, catalyst and application for olefinic polymerization | 中国石油化工股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-3287122-A1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | Allergan Sales, LLC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2427172-B1 | A METHOD FOR TREATING OVERACTIVE BLADDERS AND A DEVICE FOR STORAGE AND ADMINISTRATION OF TOPICAL OXYBUTYNIN COMPOSITIONS | ALLERGAN SALES LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CHRISTIAN NOE AND ERNST MUTSCHLER | 2002-11-21 | — | — | US | disclosed |
| EP-1242589-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE ALPHA-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6307060-B1 | ANTISPASMODIC AGENTS | Noe, Christian | 2001-10-23 | — | — | US | disclosed |
| WO-2001048175-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE α-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
| US-6231885-B1 | CONTROLLED RELEASE MONOLITHIC PATCH FOR TRANSDERMAL ADMINISTERING OF DRUGS | PERMATEC TECHNOLOGIE AG (CH) | 2001-05-15 | — | — | US | disclosed |
| EP-0913158-A1 | Transdermal patch comprising a combination of two or more fatty acids or alcohols as permeation enhancers | PERMATEC TECHNOLOGIE AG (CH) | 1999-05-06 | — | — | EP | disclosed |
| US-5294737-A | Hydrolysis, cyclization, condensation | THE RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK (US) | 1994-03-15 | — | — | US | disclosed |
| US-5036107-A | Treatment of neurogenic bladder disorders | MARION MERRELL DOW INC. (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173536-A1 | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments | CYP2A13, CYP3A43, HCAR2 | LMNA 1524/4885CYP2D6 12/4885CYP2C9 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.